zalcitabine has been researched along with Disease Exacerbation in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (89.29) | 18.2507 |
| 2000's | 3 (10.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bettendorf, DM; Christopherson, C; D'Aquila, RT; Hammer, SM; Katzenstein, DA; Lathey, JL; Tierney, C | 1 |
| Abdul, HM; Ansari, MA; Butterfield, DA; Nath, A; Opii, WO; Sultana, R | 1 |
| Abrams, D; DeMets, DL; Fleming, TR; Goldman, A; Korvick, J; Launer, C; Neaton, JD | 1 |
| Boucher, CA; Hill, A; Ingrand, D; Katlama, C; Kitchen, V; McBride, M; McDade, H; Tubiana, R; van Leeuwen, R; Weber, J | 1 |
| Richman, DD | 1 |
| Allan, JD; Arduino, JM; Collier, AC; Feinberg, JE; Fischl, MA; Goldsmith, JC; Powderly, WG; Stanley, K; Stein, DS | 1 |
| Abrams, DI; Carlin, BP; Crane, LR; Deyton, L; Goldman, AI; Korvick, JA; Launer, C | 1 |
| Jablonowski, H | 1 |
| Adams, O; Jablonowski, H; Mauss, S; Willers, R | 1 |
| Detels, R; Graham, NM; Hoover, DR; Mellors, JW; Park, LP; Phair, JP; Saah, AJ; Stein, DS | 1 |
| Cooper, DA; Harrigan, PR; Kinghorn, I; Lange, JM; Larder, BA; Lavelle, J; Lefkowitz, L; McKinnis, R; Moore, M; Mulder, JW; Pennington, KN; Ramirez-Ronda, C; Rooney, JF; Schooley, RT; St Clair, M; Steel, H | 1 |
| Balis, F; Brouwers, P; Church, J; Farley, M; Goldsmith, J; Keller, A; Lewis, LL; Mueller, B; Pizzo, PA; Rubin, M; Shearer, GM; Sloas, M; Venzon, D; Wheeler, S; Wood, L; Yuen, G | 1 |
| Abrams, D; Collins, G; Crane, L; Hodges, JS; Loveless, MO; Markowitz, N; Pettinelli, C; Reves, R; Saravolatz, LD; Stein, DS; Thompson, M; Winslow, DL | 1 |
| Millard, PS | 1 |
| Brizzi, M; Ceccherini-Nelli, L; Forastieri, G; Iuliano, R; Mazzotta, F; Mecocci, L | 1 |
| Barton, S; Blaxhult, A; Clotet, B; Goebel, FD; Hirschel, B; Katlama, C; Lundgren, JD; Pedersen, C; Phillips, AN; Vella, S | 1 |
| Byington, R; Elbeik, T; Fiscus, SA; Griffith, BP; Hammer, SM; Hughes, MD; Jackson, B; Japour, A; Katzenstein, DA; Lathey, JL; Pi, T; Rasheed, S; Reichman, R; Scott, W | 1 |
| DeMasi, R; Hill, AM; Montaner, JS | 1 |
| Kavlick, MF; Mitsuya, H; Wyvill, K; Yarchoan, R | 1 |
| Flepp, M; Jost, J; Ledergerber, B; Opravil, M; Paris, D; Ruef, C; Weber, R; Zimmerli, S | 1 |
| James, JS | 1 |
| Doepel, L; Folkers, G | 1 |
| Arduino, JM; Collier, AC; Fischl, MA; Spiegelman, D; Stanley, K | 1 |
3 review(s) available for zalcitabine and Disease Exacerbation
| Article | Year |
|---|---|
Resistance, drug failure, and disease progression.
Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Nevirapine; Pyridines; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1994 |
Studies of zidovudine in combination with didanosine and zalcitabine.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Safety; Zalcitabine; Zidovudine | 1995 |
Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Randomized Controlled Trials as Topic; Survival Rate; Time Factors; Zalcitabine; Zidovudine | 1999 |
16 trial(s) available for zalcitabine and Disease Exacerbation
| Article | Year |
|---|---|
Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; DNA, Viral; HIV-1; Humans; Multivariate Analysis; Prognosis; RNA, Viral; Zalcitabine; Zidovudine | 2003 |
Insights from monitoring the CPCRA didanosine/zalcitabine trial. Terry Beirn Community Programs for Clinical Research on AIDS.
Topics: Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; Confidence Intervals; Didanosine; Disease Progression; Drug Monitoring; HIV Infections; Humans; National Institutes of Health (U.S.); Prognosis; Randomized Controlled Trials as Topic; Research Design; Severity of Illness Index; United States; Zalcitabine | 1995 |
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.
Topics: Adult; Antiviral Agents; beta 2-Microglobulin; Biomarkers; Biopterins; CD4 Lymphocyte Count; Disease Progression; Dose-Response Relationship, Drug; HIV Core Protein p24; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Neopterin; Zalcitabine | 1995 |
Resistance, drug failure, and disease progression.
Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Nevirapine; Pyridines; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1994 |
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; CD4-Positive T-Lymphocytes; Combined Modality Therapy; Disease Progression; Double-Blind Method; Female; HIV Core Protein p24; Humans; Lymphocyte Count; Male; Zalcitabine; Zidovudine | 1995 |
Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection.
Topics: Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Didanosine; Disease Progression; Follow-Up Studies; HIV Infections; HIV-1; Humans; Regression Analysis; Survival Rate; Treatment Outcome; Zalcitabine | 1996 |
Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Survival Analysis; Treatment Outcome; Zalcitabine; Zidovudine | 1996 |
Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; HIV Seropositivity; Humans; Longitudinal Studies; Male; Proportional Hazards Models; Zalcitabine; Zidovudine | 1996 |
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Phenotype; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Disease Progression; Female; HIV Core Protein p24; HIV Infections; Humans; Infant; Lamivudine; Male; Pancreatitis; Risk Factors; RNA, Viral; Treatment Outcome; Zalcitabine | 1996 |
Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
Topics: Adolescent; Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Male; Survival Analysis; Zalcitabine; Zidovudine | 1996 |
Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Rese
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Risk; Survival Analysis; Zalcitabine; Zidovudine | 1996 |
Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Health Services; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1997 |
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.
Topics: Adult; Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Disease Progression; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Multivariate Analysis; Prognosis; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1998 |
The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; RNA, Viral; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1998 |
Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection?
Topics: Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Prognosis; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 2001 |
10 other study(ies) available for zalcitabine and Disease Exacerbation
| Article | Year |
|---|---|
Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)--2',3'-dideoxycytidine (ddC): relevance to HIV-dementia.
Topics: AIDS Dementia Complex; Animals; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Bridged-Ring Compounds; Caspase 3; Cerebral Cortex; Cytochromes c; Disease Progression; Gerbillinae; Humans; Lamivudine; Male; Mitochondria; Nerve Tissue Proteins; Neuroprotective Agents; Norbornanes; Oxidation-Reduction; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Inhibitors; Synaptosomes; Thiocarbamates; Thiones; Tyrosine; Zalcitabine | 2007 |
Treatment of late-state HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Combinations; HIV Infections; Humans; Randomized Controlled Trials as Topic; Reproducibility of Results; Reverse Transcriptase Inhibitors; Treatment Outcome; Zalcitabine; Zidovudine | 1997 |
Correlation between plasma HIV-1 RNA levels and the rate of immunologic decline.
Topics: Anti-HIV Agents; beta 2-Microglobulin; CD4 Lymphocyte Count; Didanosine; Disease Progression; DNA, Viral; Drug Therapy, Combination; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Longitudinal Studies; RNA, Viral; Stavudine; Viral Load; Viremia; Virus Replication; Zalcitabine; Zidovudine | 1997 |
[Initial administration of a protease inhibitor delays the progression of AIDS by half time].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Disease Progression; HIV Infections; HIV Protease Inhibitors; Humans; Time Factors; Zalcitabine; Zidovudine | 1997 |
Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Dideoxynucleosides; Disease Progression; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Stavudine; Survival Analysis; Zalcitabine; Zidovudine | 1998 |
Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Didanosine; Dideoxynucleosides; Disease Progression; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Point Mutation; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1998 |
Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Disease Progression; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir; Stavudine; Switzerland; Treatment Failure; Viral Load; Zalcitabine; Zidovudine | 1999 |
Saquinavir prolongs survival and slows disease progression.
Topics: CD4 Lymphocyte Count; Disease Progression; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Quinolines; Saquinavir; Survival Rate; Zalcitabine | 1996 |
3TC: combination trial stopped early as clinical benefit shown.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Placebos; Treatment Failure; Zalcitabine; Zidovudine | 1996 |
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as Topic; Clone Cells; Dendritic Cells; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-10; Killer Cells, Natural; Lamivudine; Male; Nevirapine; Pyridines; Receptors, Cytokine; Reverse Transcriptase Inhibitors; Ritonavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |